#United States #Chicago #Caris Life Sciences #Precision Oncology #ASCO 2026

Caris Life Sciences at ASCO 2026: Pioneering Multi-omic Biomarker Research

Caris Life Sciences®, renowned as a leader in precision medicine and next-generation AI TechBio, is gearing up for a significant presence at the upcoming 2026 American Society of Clinical Oncology (ASCO) Annual Meeting. Scheduled between May 29 and June 2 in Chicago, IL, the company will present a total of 32 innovative studies in collaboration with more than 60 institutions, showcasing advancements in multi-omic biomarker research and real-world evidence applications.

The studies span various cancer types, including notable research on breast, colorectal, lung, endometrial, and renal cell carcinomas. By harnessing the power of retrospective real-world analyses, these studies aim to deepen the understanding of tumor biology, ultimately informing precision oncology treatment approaches. In a landscape where data-driven decision-making is crucial, Caris underscores the utility of comprehensive molecular profiling in understanding and treating cancer more effectively.

Dr. George W. Sledge, Jr., the Executive Vice President and Chief Medical Officer at Caris, expressed pride in the company's collaboration with leading academic and clinical institutions. He emphasized how these partnerships facilitate large-scale, multi-omic research and the generation of real-world evidence, both vital for enhancing precision oncology.

Among the major highlights set for presentation at ASCO is a study assessing novel biomarker insights crucial for precision medicine. One particular exploration investigates the impact of genetic ancestry on ultraviolet (UV)-related mutations in melanoma and their correlation with immunotherapy responses. Another pivotal analysis identifies ESR1 amplification in breast cancer as a specific genomic subtype associated with reduced survival rates and lesser benefits from CDK4/6 inhibitor therapies. This dual focus on genetic factors and treatment outcomes represents an exciting frontier in understanding cancer vulnerabilities and therapeutic impacts.

Collaborative Insights Across Borders

The research presented by Caris at ASCO 2026 underscores global collaboration in cancer research. The studies include contributions from prominent institutions such as Dana-Farber Cancer Institute, Mayo Clinic, Memorial Sloan Kettering Cancer Center, and the National Cancer Institute, with research spanning not only the United States but also Europe, Asia, and the Middle East. This international collaboration illustrates a collective commitment to advancing cancer treatment through science and innovation.

Each study tackles significant questions in oncology, such as understanding immune microenvironments and predictive modeling of treatment responses. For instance, one study explores the clinical impact of MSH3 loss-of-function alterations in patients across various cancer types treated with immune checkpoint blockade, promising to offer valuable insights into predictive factors for immunotherapy effectiveness.

Landmark Presentations at ASCO

The ASCO 2026 event will also feature rapid oral presentations and posters that reflect the cutting-edge nature of ongoing research in the field. Noteworthy presentations include:

• - Mitochondrial DNA Expression: This study seeks to define metabolic and immune states in colorectal cancer, emphasizing the critical role of mitochondrial factors in cancer biosystems.
• - Distinct Patterns of HER2-Positive Invasive Lobular Carcinoma: By analyzing real-world cohorts, this study aims to uncover late recurrence patterns and immune landscape influencing patient outcomes.
• - Genomic and Transcriptomic Profiling: Studies analyzing features of aggressive neuroendocrine carcinomas aim to visualize tumor characteristics across various forms of cancer.

The breadth of research being showcased at ASCO reflects Caris’s dedication to facilitating innovative solutions through advanced technologies. By leveraging next-generation sequencing and AI, Caris Life Sciences aims to unlock the intricacies of disease and create a robust platform for precision oncology.

About Caris Life Sciences

Caris Life Sciences, headquartered in Irving, Texas, has positioned itself as a leader in patient-centric precision medicine. The firm is dedicated to transforming healthcare via comprehensive molecular profiling and advanced AI technologies. With offices across various locations, including Japan and Switzerland, Caris aims to enhance clinical outcomes for cancer patients across the globe.

As the ASCO 2026 approaches, anticipation builds for the crucial insights that will emerge from Caris Life Sciences’ innovative research, paving the way for future breakthroughs in precision oncology. The company will showcase these findings at their booth #27059 during the conference, and full abstracts will be accessible on their website following the meeting. This event marks another step forward in the ever-evolving landscape of cancer treatment, guided by data-driven insights and a commitment to excellence.